- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03186586
Ulipristal Versus Placebo for Women With Bleeding Induced by Mirena
Ulipristal Versus Placebo for Women With Bleeding Induced by Mirena, a Randomized Clinical Trial
Objectives: To assess if the administration of ulipristal acetate (UPA) in users of the levonorgestrel-releasing intrauterine system (LNG-IUS) with breakdown bleeding or abnormal bleeding, could be able to inhibit the bleeding and if this effect will be sustainable up to three months after treatment.
Material and methods: A total of 32 women aged between 18-45 years, users of the LNG-IUS with breakdown bleeding, abnormal bleeding or prolonged bleeding (bleeding more than 14 days) or episodes of bleeding with intervals less than 24 days). The study is an experimental, double blind randomized (16 women will receive UPA 5 mg/day/5 days; 16 women will receive placebo/1 time/day/5 day). The women will invited to participated at the Family Planning clinic at the day they consulted with the complaint of bleeding. That day they will allocated at random to UPA or placebo group. They will oriented to fill out a bleeding calendar through 90 days after the pill intake. In addition a ultrasonography scan will be perform before the first day of pill intake and at 90 days after.
Statistical analysis: A a pilot study the sample was estimated in 26 women (13 at each group) based at the estimative of success of 0.95 with UPA and 0.35 with placebo with significance of 0.05 and power of 80%. The sociodemographic characteristics will be analyzed as mean and SD and will compared through Mann-Whitney, Yates χ2 and Fisher exact tests as apropriate. Also, a regression analysis (Poisson analysis) with the dependent significant variables. The established level of significance will be p < 0.05.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The LNG-IUS is a contraceptive method with high efficacy, long acting, reversible with contraceptive failure between 0.1 and 0.5/100 women/year. It released 20 mcg/day of LNG with a life span duration of 5 years. LNG is a synthetic progestin, 19-northestosterone, six times more potent than progesterone, with androgenic properties and with binding with sexual hormones, receptors of human steroids, including receptors of glucocorticoids and mineralocorticoids, with minimal capacity of binding with estrogen receptors. At endometrium level it induce antiproliferative effect and strong expression of local markers and endometrial decidualization, including the prolactin receptor and insulin-like growth factor. The mechanism of action includes effect upon cervical mucus which affects the sperm movements through the reproductive tract which affects fertilization. In some women could be ovulation inhibition. One of the main reason for discontinuation is breakdown bleeding, increase bleeding or abnormal bleeding including heavy menstrual bleeding (HMB) and spotting which is common at the first six month of use. Despite the fact that it is the main cause of discontinuation, there is no effective treatment for these cases. An effective treatment could help in the reduction of reduce the rates of discontinuation, improved the cost-effectiveness and quality of life of users.
A selective progesterone receptor modulator (SPRM) is Ulipristal Acetate (UPA) is approved in the European Union as Esmya® as a tretament to reduce the ueterine leiomyomas at te dose of 5 mg/day and it under evaluation at the dose of 5-10 mg as oral contraceptive.
This could be an option of treatment for HMB or abnormal bleeding induced by the LNG-IUS. UPA is agonist/antagonist and binding with progesterone to the receptor level. It has ovarian and endometrial activity, with dose-dependent effect in inhibition of ovulation and maturation of the endometrium. There are restricted evidences, that the administration of UPA induce a quick endometrial atrophy and stop the abnormal bleeding.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
SP
-
Campinas, SP, Brazil, 13083888
- Recruiting
- University of Campinas
-
Contact:
- Luis Bahamondes, Md
- Phone Number: 209 55 19 32892856
- Email: bahamond@caism.unicamp.br
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Women with complaints of abnormal bleeding during use of Mirena independently of the length of use
Exclusion Criteria:
Delivery in the last six months Breastfeeding Hematological disorder Use of anticoagulants Uterine leiomioma
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Ulipristal acetate 5mg/day/five days
Women with abnormal bleeding during use of Mirena will allocate to UPA or placebo Ulipristal acetate at 5mg/day/five days Ulipristal 5mg daily for 5 days at the bleeding episode
|
5mg/day/five days
|
PLACEBO_COMPARATOR: Placebo 1 pill/day/five days
Women with abnormal bleeding during use of Mirena will allocate to UPA or placebo Placebo at 1pill/day/five days Placebo one pill a day for 5 days at the bleeding episode
|
Placebo one pill a day for 5 days at the bleeding episode
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Uterine bleeding control (stop bleeding)
Time Frame: Three months
|
Uterine bleeding control (stop bleeding) among users of Mirena after use of UPA or placebo
|
Three months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Endometrial control
Time Frame: Three months
|
Endometrial thickness
|
Three months
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CEMICAMP
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heavy Menstrual Bleeding
-
University Hospital, GhentRecruitingMenstrual Bleeding, HeavyBelgium
-
LiNA MedicalSyntactx; West Virginia University, Pathology Laboratory for Translational... and other collaboratorsUnknownMenorrhagia | Heavy Menstrual Bleeding
-
University of EdinburghNHS LothianCompleted
-
Ferring PharmaceuticalsCompletedMenorrhagia | Heavy Menstrual BleedingUnited States
-
BayerTerminatedUterine Fibroids and Heavy Menstrual BleedingJapan
-
Nationwide Children's HospitalCompleted
-
Sydney Centre for Reproductive Health ResearchMerck Sharp & Dohme LLCUnknown
-
Uteron Pharma S.A.Completed
-
Ferring PharmaceuticalsCompletedMenorrhagia | Heavy Menstrual BleedingUnited States
-
Birmingham Women's NHS Foundation TrustUnknownHeavy Menstrual Bleeding
Clinical Trials on Ulipristal acetate
-
Northwestern UniversityUnknown
-
PregLem SACompletedUterine FibroidsUnited Kingdom, Belgium, Czechia, France, Germany, Hungary, Italy, Latvia, Lithuania, Romania, Ukraine
-
Eunice Kennedy Shriver National Institute of Child...HRA PharmaCompletedLeiomyomaUnited States
-
Population CouncilUnknown
-
Stanford UniversityCompleted
-
Northwestern UniversitySociety of Family PlanningRecruitingContraception | Contraceptive Usage | Reproductive IssuesUnited States
-
Instituto Valenciano de Infertilidad, IVI VALENCIATerminated
-
Manchester University NHS Foundation TrustUniversity of ManchesterCompleted
-
ASSOCIATION POUR LE DEVELOPPEMENT EN FECONDATION...Gedeon Richter Plc.CompletedInfertility, Female | Fibroid UterusFrance, New Caledonia
-
Fundació Institut de Recerca de l'Hospital de la...UnknownTreatment Side Effects | Leiomyoma, Uterine | Liver InjurySpain